Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907044 | 1.00 | DPP4 (0.49) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| SCHEMBL990478 | 1.00 | DPP4 (0.49) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL5733961 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL7300435 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL10867215 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Hydrochloric Acid SCHEMBL5733967 | 0.98 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Serine SCHEMBL3839203 | 0.94 | DPP4 (0.45) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| Trifluoroacetic Acid SCHEMBL5735676 | 0.91 | GRB2 (0.46) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| SCHEMBL3839201 | 0.86 | DPP4 (0.43) | DPP4DPP8DPP9CYP1A2OPRD1 | |
| SCHEMBL5207691 | 0.86 | DPP4 (0.49) | DPP4DPP8DPP9OPRD1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 726 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250186539-A2 | METHODS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2025-06-12 | — | — | US | claimed |
| CN-118864883-B | Audio-visual dance generation method and system based on diffusion model and cross-mode collaboration | 浙江大学 | 2025-04-29 | — | — | CN | claimed |
| WO-2025051920-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR INHIBITORS | SANOFI (FR) | 2025-03-13 | — | — | WO | claimed |
| CN-119402531-A | Ocean monitoring data processing method based on AI and Internet of things technology | 青岛启弘信息科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119334361-A | High-precision stable aiming tracking error correction method for two-dimensional turntable | 中国科学院西安光学精密机械研究所 | 2025-01-21 | — | — | CN | claimed |
| EP-4464715-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BicycleTx Limited (GB) | 2024-11-20 | — | — | EP | claimed |
| CN-118864883-A | Audio-visual dance generation method and system based on diffusion model and cross-modal collaboration | 浙江大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118870391-A | Wireless sensor network gateway optimization method and system | 深圳市奇特龙科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20240325554-A1 | METHODS FOR TREATING CANCER | BICYCLE TX LTD (GB) | 2024-10-03 | — | — | US | claimed |
| WO-2021019245-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 | BICYCLETX LIMITED (GB) | 2021-02-04 | — | — | WO | claimed |
| WO-2021019246-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2021-02-04 | — | — | WO | claimed |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | claimed |
| EP-3678683-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| CN-111372942-A | β -catenin function modulating agents and methods thereof | 弗格制药有限公司 | 2020-07-03 | — | — | CN | claimed |
| WO-2019243832-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BICYCLETX LIMITED (GB) | 2019-12-26 | — | — | WO | claimed |
| US-10329321-B2 | Site-selective functionalization of proteins using traceless affinity labels | Krantz, Alexander (US) | 2019-06-25 | — | — | US | claimed |
| WO-2019051327-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | claimed |
| EP-3413921-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABLES | Krantz, Alexander (US) | 2018-12-19 | — | — | EP | claimed |
| WO-2017139329-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABLES | KRANTZ ALEXANDER (US) | 2017-08-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325554-A1 | METHODS FOR TREATING CANCER | CD44, TUBB4A, TUBB3 | DPP4 2226/4885DPP8 4128/4885DPP9 3621/4885 |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | CTNNB1, CTNNBL1, CTNNA1 | DPP4 616/4885DPP8 268/4885DPP9 283/4885 |
| US-10329321-B2 | Site-selective functionalization of proteins using traceless affinity labels | MYCBP, FABP3, STUB1 | DPP4 4207/4885DPP8 3410/4885DPP9 4104/4885 |
| US-20250186539-A2 | METHODS FOR TREATING CANCER | CD44, TUBB4A, TUBB3 | DPP4 2226/4885DPP8 4128/4885DPP9 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.